Shockwave Medical has registered for an upcoming initial public offering worth $70 million, according to recently posted SEC filings.
The Santa Clara, Calif.-based vascular tech developer is looking to list its common stock on the Nasdaq Global Market under the symbol “SWAV,” according to the filing.
Net proceeds from the offering are slated to support ongoing commercialization of the company’s Intravascular Lithotripsy, or IVL, devices, according to the filing. Funds will also be used to expand the company’s sales force, medical affairs teams and educational efforts, as well as for possible strategic transactions and for general corporate purposes.
Shockwave Medical has not yet stated how many shares it plans to offer in the round or the pricing for the shares.
Last month, Shockwave Medical said that it launched a U.S. pivotal trial for its coronary lithotripsy device, which is designed to prepare heavily calcified coronary lesions for stenting.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.